New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:29 EDTATNM, ESPR, TGTX, ZIOP, KBIO, HZNP, EBIO, OMER, FPRX, RGDO, DRNABioCentury to hold a conference
Future Leaders in the Biotech Industry Conference is being held in New York on March 28.
News For ATNM;RGDO;FPRX;OMER;EBIO;HZNP;KBIO;ZIOP;TGTX;ESPR;DRNA From The Last 14 Days
Check below for free stories on ATNM;RGDO;FPRX;OMER;EBIO;HZNP;KBIO;ZIOP;TGTX;ESPR;DRNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
16:57 EDTHZNPHorizon Pharma files automatic ordinary share shelf
10:46 EDTHZNPHorizon Pharma backs FY15 revenue view $380M-$405M, consensus $376.94M
Backs FYT15 adjusted EBITDA view $150M-$170M
10:45 EDTHZNPHorizon Pharma backs FY14 revenue view $270M-$280M, consensus $277.56M
Subscribe for More Information
September 18, 2014
19:50 EDTHZNPHorizon Pharma trading halted, pending news
Subscribe for More Information
09:19 EDTHZNPHorizon Pharma announces holder approval of Vidara acquisition
Subscribe for More Information
September 16, 2014
10:30 EDTTGTXTG Therapeutics capitlal raise unlikely, says Roth Capital
Subscribe for More Information
06:21 EDTHZNPHorizon Pharma to host special shareholder meeting
Special shareholder meeting to consider and seek shareholder approval of the acquisition of Vidara Therapeutics, will be held in Deerfield, IL on September 18 at 9 am.
September 15, 2014
16:10 EDTFPRXFive Prime announces option exercise by GlaxoSmithKline to obtain license
Subscribe for More Information
14:10 EDTTGTXTG Therapeutics SPA for CLL study earlier than expected, says Ladenburg
Ladenburg said TG Therapeutics reached an agreement with the FDA regarding a Special Protocol Assessment, or SPA, for a trial of its combo treatment for Chronic Lymphocytic Leukemia, or CLL, "quite ahead" of the firm's December expectation. The firm believes there is a relatively high probability for TG's combo to meet the specified primary endpoint and increased its price target on the stock to $22 from $18.
08:12 EDTHZNPHorizon Pharma valuation at attractive entry point, says Cowen
Subscribe for More Information
07:03 EDTTGTXTG Therapeutics announces SPA agreement with FDA for Phase 3 trial of TG-1101
Subscribe for More Information
September 10, 2014
07:05 EDTATNMRodman & Renshaw to hold a conference
Subscribe for More Information
September 9, 2014
10:09 EDTHZNPHorizon Pharma initiated with an Outperform at Avondale (pre-open)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use